Developments in PK/PD: optimising efficacy and prevention of resistance. A critical review of PK/PD in in vitro models

被引:45
作者
MacGowan, A [1 ]
Bowker, K [1 ]
机构
[1] Univ Bristol & N Bristol NHS Trust, Southmead Hosp, Bristol Ctr Antimicrobial Res & Evaluat, Dept Med Microbiol, Bristol BS10 5NB, Avon, England
关键词
resistance; PK/PD; antimicrobial pharmacodynamics;
D O I
10.1016/S0924-8579(02)00027-4
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
In vitro pharmacokinetic models are excellent tools with which to study an antibacterial's pharmacodynamics (PD), being flexible, adaptable, low cost, and correlating well with animal and human systems. They can be used to perform simple descriptive studies on antibacterial effect, determine the dominant pD factor and its magnitude for antibacterial effect, and finally be used to assess the effect of dosing on emergence of resistance. A wide range of model designs are used and some standardisation maybe of value in the near future, however it is clear that in vitro models in conjunction with animal studies and human trials offer an excellent way of studying drug dosing to optimise outcomes. (C) 2002 Elsevier Science B.V. and International Society of Chemotherapy. All rights reserved.
引用
收藏
页码:291 / 298
页数:8
相关论文
共 35 条
[1]   The effects of NorA inhibition on the activities of levofloxacin, ciprofloxacin and norfloxacin against two genetically related strains of Staphylococcus aureus in an in-vitro infection model [J].
Aeschlimann, JR ;
Kaatz, GW ;
Rybak, MJ .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1999, 44 (03) :343-349
[2]   COMPARATIVE-STUDY WITH ENOXACIN AND NETILMICIN IN A PHARMACODYNAMIC MODEL TO DETERMINE IMPORTANCE OF RATIO OF ANTIBIOTIC PEAK CONCENTRATION TO MIC FOR BACTERICIDAL ACTIVITY AND EMERGENCE OF RESISTANCE [J].
BLASER, J ;
STONE, BB ;
GRONER, MC ;
ZINNER, SH .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1987, 31 (07) :1054-1060
[3]  
BOWKER KE, 2001, 41 INT C ANT AG CHEM, P10
[4]  
BOWKER KE, 2000, 40 INT C ANT AG CHEM, P9
[5]   Bactericidal activity of moxifloxacin compared to grepafloxacin and clarithromycin against Streptococcus pneumoniae and Streptococcus pyogenes investigated using an in vitro pharmacodynamic model [J].
Esposito, S ;
Noviello, S ;
Ianniello, F .
JOURNAL OF CHEMOTHERAPY, 2000, 12 (06) :475-481
[6]   Comparative pharmacodynamics of moxifloxacin and levofloxacin in an in vitro dynamic model:: prediction of the equivalent AUC/MIC breakpoints and equiefficient doses [J].
Firsov, AA ;
Lubenko, IY ;
Vostrov, SN ;
Kononenko, OV ;
Zinner, SH ;
Portnoy, YA .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2000, 46 (05) :725-732
[7]   Prediction of the antimicrobial effects of trovafloxacin and ciprofloxacin on staphylococci using an in-vitro dynamic model [J].
Firsov, AA ;
Vasilov, RG ;
Vostrov, SN ;
Kononenko, OV ;
Lubenko, IY ;
Zinner, SH .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1999, 43 (04) :483-490
[8]   Inter- and intraquinolone predictors of antimicrobial effect in an in vitro dynamic model: New insight into a widely used concept [J].
Firsov, AA ;
Shevchenko, AA ;
Vostrov, SN ;
Zinner, SH .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1998, 42 (03) :659-665
[9]   Prediction of the effects of inoculum size on the antimicrobial action of trovafloxacin and ciprofloxacin against Staphylococcus aureus and Escherichia coli in an in vitro dynamic model [J].
Firsov, AA ;
Vostrov, SN ;
Kononenko, OV ;
Zinner, SH ;
Portnoy, YA .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1999, 43 (03) :498-502
[10]  
FIRSOV AA, 1998, 6 INT S NEW QUIN COL, P7